PLUXEE NV PLX 深 滬
等待開盤 05-20 09:30:00 美东时间
1.90
-0.010
-0.52%
華盛通- 最 高1.985
- 今 開1.91
- 成交量 74.41万股
- 最 低 1.88
- 昨 收 1.91
- 總市值 1.53亿
- 52周最高 3.19
- 市盈率 靜 --
- 換手率 0.92%
- 52周最低 1.32
- 委 比 -22.22%
- 總股本 8057.16万
- 歷史最高 77.00
- 量 比 0.63
- 振 幅 5.50%
- 歷史最低 0.70
- 每 手 1
- 風險率 0.45%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Protalix reaffirms $78M-$83M 2026 revenue outlook following $25M Elfabrio milestone
Earnings Call Insights: Protalix BioTherapeutics (PLX) Q1 2026 Management View “During the quarter, we received a $25 million milestone from Chiesi, following the European Commission approval of Elfab...
05-13 23:52
Earnings Scheduled For May 13, 2026
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11
Protalix BioTherapeutics Q1 EPS $0.05 Misses $0.06 Estimate, Sales $33.750M Beat $11.468M Estimate
Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.06 by 16.67 percent. This is a 200 percent increase over losses of $(0.05) per share
05-13 19:02
Protalix BioTherapeutics give Q1 results
Protalix BioTherapeutics press release (PLX): Q1 GAAP EPS of $0.22 Revenue of $33.75M (+233.8% Y/Y) The Company reaffirms its previously stated 2026 revenue expectations: Total revenue in 2026 to ra...
05-13 18:53
Protalix Q1 FY26 swings to net income of $18.32 million; revenue more than doubled to $33.75 million
Protalix Q1 FY26 swings to net income of $18.32 million; revenue more than doubled to $33.75 million Protalix BioTherapeutics swung to net income of USD 18.32 million, or USD 0.23 per share, from a net loss of USD 3.62 million, or USD (0.05) per share. Revenue climbed to USD 33.75 million from USD 1
05-13 18:50
Protalix BioTherapeutics Q1 Earnings Preview
Protalix BioTherapeutics (PLX) is scheduled to announce Q1 earnings results on Wednesday, May 13th, before market open. The consensus EPS estimate is -$0.01, and the consensus revenue estimate is $11....
05-13 02:07
美股大行评级 | 最高700美元！大摩、瑞银等10家大行集体上调美光目标价；通用磨坊、梅西百货、SailPoint等遭多家大行下调目标价
今日重点评级关注：RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从32美元升至35美元；巴克莱：维持CytomX医疗"超配"评级，目标价从10美元升至16美元
03-20 15:53
Protalix targets $78M–$83M 2026 revenue with EU milestone, advancing PRX-115
Earnings Call Insights: Protalix BioTherapeutics (PLX) Q4 2025 Management View Dror Bashan, President and CEO, announced that the European Commission approved the 2 milligram per kilogram every 4-week...
03-18 22:13
Earnings Scheduled For March 18, 2026
Companies Reporting Before The Bell • SailPoint (NASDAQ:SAIL) is estimated to r...
03-18 19:11
Protalix BioTherapeutics Expects FY26 Total Revenue To Range From ~$78M To $83M Including $25M Milestone Which Protalix Is Entitled To From Chiesi
Financial Outlook: Building Durable Growth and Long–Term ValueProtalix enters 2026 with a profitable commercial business through its partnerships and a focused pipeline aligned to areas of high unmet need. The
03-18 19:01
